What Is Metronidazole?
Metronidazole is a broad-spectrum antibiotic and antiprotozoal medication used to treat a wide variety of infections caused by anaerobic bacteria and certain parasites. Marketed under the brand name Flagyl in the United States, metronidazole is one of the most widely prescribed anti-infective agents globally. Its unique mechanism of action, excellent bioavailability, and broad tissue penetration make it indispensable in clinical medicine.
Discovered in 1959 by Rhône-Poulenc and first used clinically in 1960 for trichomoniasis, metronidazole was subsequently found to be effective against anaerobic bacteria, leading to expanded use across multiple medical specialties. It is included on the World Health Organization’s Model List of Essential Medicines and is considered one of the most cost-effective antibiotics available.
Mechanism of Action
Metronidazole is a prodrug that exerts its antimicrobial activity through a unique reductive activation mechanism. After entering susceptible cells, the nitro group of metronidazole is reduced by bacterial or protozoal nitroreductase enzymes (specifically ferredoxin or flavodoxin redox systems) to form reactive intermediate compounds, including nitro radicals and nitroso derivatives.
These reactive metabolites cause DNA strand breakage, inhibit nucleic acid synthesis, and disrupt bacterial DNA structure and function, leading to rapid cell death. The selectivity of metronidazole arises because the reductive activation only occurs efficiently in anaerobic or microaerophilic environments — thus, it specifically targets anaerobic bacteria and microaerophilic protozoa while sparing aerobic bacteria and host cells.
Metronidazole exhibits concentration-dependent bactericidal activity, meaning higher concentrations kill bacteria more rapidly and extensively. It has excellent tissue penetration, reaching therapeutic concentrations in most body fluids and tissues, including the central nervous system, bone, and abscess cavities.
Uses and Indications
Anaerobic Bacterial Infections
Metronidazole is the drug of choice for many anaerobic infections, particularly those involving Bacteroides fragilis, Clostridium species, Peptostreptococcus, and Fusobacterium. Common indications include:
- Intra-abdominal infections: Peritonitis, diverticulitis, appendicitis, liver abscess
- Pelvic infections: Pelvic inflammatory disease (PID), endometritis, tubo-ovarian abscess
- Skin and soft tissue infections: Diabetic foot infections, decubitus ulcers, surgical wound infections
- Brain abscess: Excellent CNS penetration makes it the treatment of choice
- Bone and joint infections: Osteomyelitis involving anaerobes
- Dental infections: Periodontitis, pericoronitis, dental abscess (often combined with amoxicillin)
- C. difficile infection: Oral metronidazole is a first-line treatment for mild-to-moderate disease
Protozoal Infections
- Trichomoniasis: Single-dose therapy (2g) for Trichomonas vaginalis infection
- Giardiasis: Metronidazole 250mg three times daily for 5–7 days
- Amebiasis: Metronidazole 500–750mg three times daily for 7–10 days for intestinal and hepatic amebiasis
- Balantidiasis: Metronidazole 500mg three times daily for 5–7 days
Helicobacter pylori Eradication
Metronidazole is used in combination with a PPI and another antibiotic (such as clarithromycin or tetracycline) as part of quadruple therapy for H. pylori eradication, particularly in areas with high clarithromycin resistance.
Dosage and Administration
| Condition | Metronidazole Dose | Route | Duration |
|---|---|---|---|
| Trichomoniasis | 2g single dose | Oral | 1 day |
| Giardiasis | Metronidazole 500mg twice daily | Oral | 5–7 days |
| Amebiasis (intestinal) | Metronidazole 500–750mg three times daily | Oral | 7–10 days |
| Anaerobic infection (moderate) | Metronidazole 500mg every 8 hours | Oral/IV | 7–14 days |
| Anaerobic infection (severe) | Metronidazole 500mg IV every 8 hours | IV | 7–14 days |
| Pelvic inflammatory disease | Metronidazole 500mg twice daily | Oral | 14 days |
| C. difficile (mild-moderate) | Metronidazole 500mg three times daily | Oral | 10–14 days |
| Brain abscess | Metronidazole 500mg IV every 6–8 hours | IV | 4–8 weeks |
Administration: Metronidazole should be taken with food to minimize gastrointestinal irritation. Tablets should be swallowed whole with water. The intravenous formulation is reserved for patients unable to take oral medication or for severe infections requiring high tissue concentrations.
Side Effects
Common Side Effects (5–20% of patients)
- Metallic taste (most common — affects up to 20% of patients)
- Nausea and vomiting
- Loss of appetite
- Diarrhea
- Abdominal cramping
- Headache
- Darkening of urine (harmless — due to metabolite excretion)
Serious Side Effects (rare, <1%)
- Peripheral neuropathy: Numbness, tingling, or burning sensation in extremities. May be irreversible if not promptly recognized and discontinued
- CNS toxicity: Seizures, encephalopathy, cerebellar ataxia, dizziness, confusion
- Severe skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis
- Pancreatitis: Rare cases reported
- Leukopenia/neutropenia: Reversible reduction in white blood cell count
- Hepatotoxicity: Rare elevation of liver enzymes
- Disulfiram-like reaction: Severe nausea, vomiting, flushing, and tachycardia when alcohol is consumed within 48 hours of metronidazole
Drug Interactions
Metronidazole has several clinically important drug interactions:
- Alcohol (Disulfiram-like reaction): Absolutely contraindicated — avoid alcohol during therapy and for 48 hours after the last dose
- Warfarin: Metronidazole potentiates warfarin effect — increased INR and bleeding risk. Monitor INR closely
- Lithium: Increased lithium levels — risk of toxicity
- Phenytoin: Increased phenytoin levels
- Phenobarbital: Reduced metronidazole efficacy (enzyme induction)
- Disulfiram: Risk of psychosis and confusion — avoid combination
- Cimetidine: Increased metronidazole levels
- Cholestyramine: Reduced metronidazole absorption
Comparison with Other Anti-anaerobic Antibiotics
| Drug | Spectrum | Bioavailability | Oral option | Typical Dose |
|---|---|---|---|---|
| Metronidazole | Anaerobes, protozoa | ~100% | Yes | Metronidazole 500mg tid |
| Clindamycin | Anaerobes, Gram+ cocci | ~90% | Yes | 300–450mg qid |
| Piperacillin-Tazobactam | Broad (incl. anaerobes) | N/A (IV only) | No | 3.375g IV q6h |
| Carbapenems | Broadest spectrum | N/A (IV only) | No | 500mg–1g IV q6–8h |
| Vancomycin (oral) | C. difficile only | Non-absorbable | Yes | 125mg qid |
Affordable Generic Metronidazole and Pricing
Generic metronidazole is widely manufactured in India and other countries at very low cost. It is one of the most affordable essential antibiotics available globally.
Indian Generic Metronidazole Pricing: Approximately $4–$8 for a 30-tablet supply of metronidazole 500mg.
US Brand Flagyl Pricing: Approximately $45–$75 for a 30-tablet supply.
US Generic Metronidazole Pricing: Approximately $10–$16 for a 30-tablet supply of metronidazole 500mg.
Indian generic manufacturers offer substantial cost savings of 50–90% compared to US retail prices while maintaining strict quality standards (WHO-GMP, USFDA, MHRA certifications). International pharmacy sourcing platforms like 984online’s Antibiotic Medications provide access to high-quality generic metronidazole for patients and healthcare providers worldwide.
FAQ
1. Can I drink alcohol while taking metronidazole?
No. Alcohol consumption during metronidazole therapy and for 48 hours after the last dose can cause a disulfiram-like reaction characterized by severe nausea, vomiting, headache, flushing, abdominal cramps, and tachycardia. This reaction occurs because metronidazole inhibits aldehyde dehydrogenase, leading to acetaldehyde accumulation.
2. Why does metronidazole cause a metallic taste?
The metallic taste (dysgeusia) is caused by metronidazole being excreted in saliva, where it binds to taste receptors. It is the most common side effect, affecting up to 20% of patients, and typically resolves within 24–48 hours after completing therapy.
3. Is metronidazole safe during pregnancy?
Metronidazole crosses the placenta and is generally avoided during the first trimester. It is classified as FDA Pregnancy Category B, meaning animal studies have not demonstrated fetal risk. Use during pregnancy should be reserved for clearly indicated infections (trichomoniasis, bacterial vaginosis) after careful risk-benefit assessment.
4. How long does it take for metronidazole to work?
Metronidazole begins working within 24–48 hours for most infections. Patients often notice symptom improvement within 1–3 days. However, the full course should be completed as prescribed, even if symptoms improve, to prevent relapse and antibiotic resistance.
5. What is the difference between metronidazole oral and vaginal formulations?
Oral metronidazole achieves systemic levels and is used for infections throughout the body. Vaginal metronidazole (gel or suppositories) is used for local treatment of bacterial vaginosis and trichomoniasis. Oral therapy is often preferred for trichomoniasis due to better partner compliance and efficacy, while vaginal gel may be used for bacterial vaginosis in appropriate cases.
Clinical Evidence and Efficacy
The clinical efficacy of metronidazole has been extensively documented across its diverse indications. A landmark multicenter trial demonstrated that intravenous metronidazole 500mg every 8 hours achieved clinical cure rates of 85-95% in patients with intra-abdominal infections when combined with appropriate Gram-negative coverage. For C. difficile infection, a Cochrane review of 15 randomized trials found that oral metronidazole 500mg three times daily for 10-14 days achieved initial clinical response rates of 72-80% in mild-to-moderate disease, with superior cost-effectiveness compared with vancomycin. In trichomoniasis, single-dose metronidazole 2g achieves parasitological cure rates exceeding 95%. For giardiasis, a meta-analysis of 20 randomized trials found that metronidazole 500mg twice daily for 5-7 days achieved clinical cure rates of 80-92%. More recently, concerns about emerging metronidazole resistance in Bacteroides species and C. difficile have highlighted the importance of antimicrobial stewardship. Despite 60 years of clinical use, metronidazole resistance rates among anaerobic bacteria remain relatively low (<5% in most surveillance studies), attesting to the sustained value of this essential antibiotic.
Safety and Precautions
Before taking metronidazole, inform your healthcare provider about:
- History of blood disorders (leukopenia, neutropenia)
- Liver disease (metronidazole is hepatically metabolized)
- Kidney disease (active metabolite accumulation)
- CNS disorders (seizures, peripheral neuropathy)
- Pregnancy or breastfeeding
- Alcohol use (must abstain during treatment and 48 hours after)
Metronidazole should be discontinued immediately if signs of peripheral neuropathy (numbness, tingling in extremities) or CNS effects (ataxia, dizziness, confusion) develop. Prolonged or repeated courses should be avoided when possible.
References
- U.S. Food and Drug Administration. Flagyl (metronidazole) Prescribing Information. Available from: https://www.accessdata.fda.gov/
- Löfmark S, Edlund C, Nord CE. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis. 2010;50(Suppl 1):S16-S23.
- Freeman CD, Klutman NE, Lamp KC. Metronidazole. A therapeutic review and update. Drugs. 1997;54(5):679-708.
- World Health Organization. WHO Model List of Essential Medicines. 2023.
- Brook I. Treatment of anaerobic infection. Expert Rev Anti Infect Ther. 2007;5(6):991-1006.
- Nagy E, Boyanova L, Justesen US. How to isolate, identify, and determine antimicrobial susceptibility of anaerobic bacteria in routine laboratories. Clin Microbiol Infect. 2018;24(11):1139-1148.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication. Prices are estimates and may vary by location and pharmacy. Complete the full course of antibiotics as prescribed.
